

**FDA Biologics 483s
2015-2019**

**5 Year Summary
of FDA
Biologics 483s
2015-2019**



Jeanne Moldenhauer

www.pda.org/bookstore

5 Year Summary of FDA Biologics 483s

Jeanne Moldenhauer

PDA
Bethesda, MD, USA
DHI Publishing, LLC
River Grove, IL, USA

www.pda.org/bookstore

10 9 8 7 6 5 4 3 2 1

ISBN: 978-1-942911-44-9

**Copyright © 2020 Jeanne Moldenhauer
All rights reserved.**

All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system or transmitted in any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America.

Where a product trademark, registration mark, or other protected mark is made in the text, ownership of the mark remains with the lawful owner of the mark. No claim, intentional or otherwise, is made by reference to any such marks in the book. Websites cited are current at the time of publication. The author has made every effort to provide accurate citations. If there are any omissions, please contact the publisher.

While every effort has been made by the publisher and the author to ensure the accuracy of the information expressed in this book, the organization accepts no responsibility for errors or omissions. The views expressed in this book are those of the author and may not represent those of either Davis Healthcare International or the PDA, its officers, or directors.



Connecting People, Science and Regulation®



PDA Global Headquarters
Bethesda Towers, Suite 150
4350 East-West Highway
Bethesda, MD 20814
United States
www.pda.org/bookstore
001-301-986-0293

Davis Healthcare International Publishing, LLC
2636 West Street
River Grove
IL 60171
United States
www.DHIBooks.com

www.pda.org/bookstore

CONTENTS

I	Introduction	I
	What is included in a FDA 483?	2
	How Does a FDA 483 Compare to a Warning Letter?	2
	Responding to a FDA 483	2
	During the inspection	3
	The actual company response to the FDA regarding the FDA 483	3
	Following the response	4
	Why Review FDA 483s?	4
	Literature Cited	5
2	Summary of Biologics FDA Observations	6
	Background	6
	Five Year Data Summaries can be found on the following pages:	
	21 CFR 600.10	7
	21 CFR 600.11	7
	21 CFR 600.12	7
	21 CFR 600.14	7
	21 CFR 600.15	7
	21 CFR 600.80	7
	21 CFR 600.81	7
	21 CFR 606.20	7
	21 CFR 606.40	8
	21 CFR 606.60	8
	21 CFR 606.65	8
	21 CFR 606.100	8
	21 CFR 606.110	10
	21 CFR 606.121	10
	21 CFR 606.140	11
	21 CFR 606.145	11
	21 CFR 606.151	11

Table of Contents

21 CFR 606.160	11
21 CFR 606.165	12
21 CFR 606.170	12
21 CFR 606.171	12
21 CFR 610.1	12
21 CFR 610.18	12
21 CFR 610.40	12
21 CFR 610.41	13
21 CFR 610.46	13
21 CFR 610.47	13
21 CFR 610.53	13
21 CFR 610.60	13
21 CFR 610.46	13
21 CFR 610.47	14
21 CFR 630.5	14
21 CFR 630.6	14
21 CFR 630.10	14
21 CFR 630.15	16
21 CFR 630.30	16
21 CFR 630.40	16
21 CFR 640.3	16
21 CFR 640.4	17
21 CFR 640.11	17
21 CFR 640.15	17
21 CFR 640.21	17
21 CFR 640.25	17
21 CFR 640.34	17
21 CFR 640.61	17
21 CFR 640.63	18
21 CFR 640.64	18
21 CFR 640.65	18
21 CFR 640.67	18
21 CFR 640.69	18
21 CFR 640.72	18
21 CFR 640.81	18
21 CFR 640.120	18
21 CFR 640.21	18
21 CFR 640.31	18
21 CFR 640.65	19
21 CFR 680.1	19
Literature Cited	19

3	Analysis of Biologics FDA 483 Summary	20
	Background	20
	What are the Most Frequently Occurring Observations?	21
	Conclusion	24
	Literature Cited	24
4	Available Resources	25
	About the Author	28